Capricor Therapeutics, Inc.
NASDAQCapricor Therapeutics is locked in the same post-earnings bear grip described earlier today — and the data published since that note has only deepened the story, not reversed it. Short interest has now reached 24.5% of the free float, with 11.2 million shares short as of May 19. That marks an 8% rise on the week and 23% over the past month — a pace that places CAPR firmly among the…
Snapshot as of 20 May 2026
Capricor Therapeutics is locked in the same post-earnings bear grip described earlier today — and the data published since that note has only deepened the story, not reversed it. Short interest has now reached 24.5% of…
Capricor Therapeutics enters the post-earnings stretch under genuine pressure: short sellers have rebuilt positions aggressively after the May 12 quarterly print, insiders sold into strength, and borrow availability…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAPR — free to start on ORTEX.
Sign up for free →Open CAPR on ORTEX